Introduction
Sudden cardiac death (SCD) remains the leading cause of mortality (up to 60%) in patients with coronary heart disease (CHD) [1, 2] and especially with history of myocardial infarction (MI). SCD is reported in approximately 12% of this population during the first year after MI. [1, 2] The majority of SCD cases are due to ventricular arrhythmias -ventricular tachycardia (VT) and ventricular fibrillation (VF).
Left ventricular ejection fraction (LVEF) is still the most important instrumental factor determining the nature of the primary SCD prevention. However, current SCD risk assessment criteria based on the LVEF only are being criticized. The risk of SCD in patients with CHD and the single criterion "LVEF < 30%" is 2.5% annually. [3] In this situation, 80-90% of ICD implantations for primary prevention of SCD are futile during the device lifetime. However, 40% of SCD cases are reported in patients with cardiac diseases and LVEF > 40%. [4, 5] The use of ICDs for primary prevention in these patients is not covered by the current guidelines. Therefore, cost-effective identification of the risk of life-threatening arrhythmias and predictors of SCD is extremely important to administer appropriate preventive treatment. [6] Several non-invasive ECG-based methods have been proposed to determine predictors of life-threatening arrhythmias and SCD, International Cardiovascular Forum Journal 11 (2017) DOI: 10.17987/icfj.v11i0.393
including heart rate turbulence (HRT) and microvolt T-wave alternans (mTWA). [1, 7, [8] [9] [10] ] Microvolt TWA has been described as a useful predictor of cardiac events in patients with various ischemic and nonischemic pathologies with or without low ejection fraction including acute coronary syndrome. [8, 9] However, there is lack of evidence concerning the use of these methods for SCD risk stratification in the post-MI patients, and they have not been included in the ESC 2015 Guidelines for management of patients with ventricular arrhythmias and the prevention of SCD, [11] despite the inclusion into ACC/AHA/ESC 2006 Guidelines for patients with severe LV dysfunction (classes of recommendations: mTWA -IIA, HRT -IIB). In recent years, deceleration capacity (DC) -parameter reflecting the ability of sinus rhythm to slow down -has also being investigated. Bauer et al. evaluated twoyear mortality after MI and showed that predictive value of DC was higher than that of the LVEF and HRV. [7] We have previously shown significantly high predictive value of HRT and mTWA during short-term follow-up (12 months). [12] Due to the relatively short follow-up (1-3 years) in most studies, we decided to investigate the long-term value of aforementioned predictors as well as DC in post-MI patients, both independently and in combination with other SCD risk factors (depressed LVEF, HRV, QRS duration, the number of premature ventricular contractions (PVCs) and the presence of VT).
Methods Design
Single-center, prospective observational cohort study with retrospective DC evaluation.
Patient groups
Between 2008 to 2010, 111 patients (age 64.1±10.5 years; 84 males and 27 females) with history of MI occurred 2 months to 36 years (median 27 [9;84] months) previously were enrolled into the study. Inclusion criteria were: MI more than 60 days prior to study entry, aged 18 years and over. Exclusion criteria were: permanent atrial flutter or atrial fibrillation, implanted pacemaker, II-III degree atrioventricular block, concomitant malignancies, hyperthyroidism, severe anemia (hemoglobin less than 90 g/l); co-administration of ivabradin or glycosides. Nineteen (17.1%) patients had percutaneous transluminal coronary angioplasty in the acute MI phase; and 45 (40.5%) had thrombolysis. Thirteen patients with Q-MI had not received revascularization treatment due to late admittance. Baseline characteristics are presented in Table 1 . Detailed characteristics of the study population have been published previously. [12] Comparable control group included 60 individuals (44 males and 16 females, age 62.5±11.6 years) with no cardiovascular comorbidity.
The study complied with the Declaration of Helsinki. Study protocol was approved by the local ethics committee. All subjects signed informed consent prior to any study procedures.
Methods
All subjects had baseline examination including medical history, 12-channel ECG, echocardiography (EchoCG) with LVEF measurement, and 24-hour ambulatory ECG monitoring with HRV (SDNN and pNN50), HRT and mTWA evaluation, recording of PVCs number and episodes of sustained/unsustained VT. 
MTWA
MTWA was measured by modified moving average method [13] in two Holter leads with GE Healthcare (GE Healthcare, Fairfield, Connecticut, U.S.) GETEMED CardioDay Holter system, ie, recorder CardioMem CM3000 and software CardioDay® v. 2.2.0.3. The detailed technique has been described previously. [13] Absolute maximum value in 24 hours (mTWAmax), mTWA values at heart rate (HR) 100 bpm and at 05.00 AM were assessed in order to standardize measurement conditions.
HRT
Regarding HRT, turbulence onset (TO) (magnitude of sinus rhythm acceleration after PVC) and turbulence slope (TS) (intensity of subsequent sinus rhythm deceleration) were evaluated. Abnormal HRT values were considered as TO≥0%, and TS≤2,5 ms/RR.
DC
DC was calculated by appropriate software via the technique based on the determination of the difference between adjacent RR intervals described by Bauer et al. [7] According to the authors, DC reflects the influence of the parasympathetic autonomic nervous system on the heart. DC > 4.5 ms corresponds to the low SCD risk; DC 2.6 to 4.5 ms corresponds to the average risk; DC ≤ 2.5 ms reflects high risk. [7] Duration of follow-up was 60 months. Primary endpoint was SCD; secondary endpoint included all non-sudden cardiovascular deaths; tertiary endpoints included non-fatal cardiovascular events and VTs. SCD was defined as death from an unexpected circulatory arrest usually due to cardiac arrhythmia occurring within an hour of the onset of symptoms. The cause of death outside the hospital was established based on the interview with relatives of the patients (personal or via telephone); all efforts were made to collect relevant medical documents. 
Statistical analysis.

Results
During the 60 months of follow-up, 19 cases of SCD (17.1%) and 11 cases of deaths from other causes (including 7 (6.3%) repeated fatal MIs and 3 (2.7%) fatal strokes) were recorded in post-MI patients. Among all-causes deaths, one case was not related to cardiovascular causes (death due to multiple organ failure after gastrectomy related to the ulcer bleeding; the cause of death was confirmed by autopsy). Four patients died in the hospital; autopsy revealed no structural changes that could be fatal. In other SCD cases, no autopsy was performed; these were deaths occurring within 60 minutes of the onset of symptoms, as well as cases of death during sleep, i.e. events that met SCD criteria. Information about these deaths was obtained from the relatives of patients; all SCD cases were qualified by the pathologists and appropriate documents were collected. All fatal MIs and fatal strokes occurred in hospital and were confirmed by medical records. In addition, tertiary endpoints were recorded in several patients including nonfatal MIs and the new-onset VT (Table 2) . Three patients received pacemakers (DDD mode) during follow-up due to onset of different cardiac blockades. All cases of implantation were performed within 3 months after the enrollment making impossible to assess the trends of mTWA, HRT and DC. However, clinical monitoring for these patients continued; two patients remained stable until the end of the follow-up. The third patient developed nonsustained VT 14 months after pacemaker implantation (confirmed by pacemaker's records), which caused a loss of consciousness and fall. VT self-terminated within 30 seconds; further patient's condition was stable. In the control group during the follow-up no deaths were recorded, and mTWA, DC and HRT showed no significant changes.
To evaluate the prognostic value of SCD predictors, all patients were divided into subgroups of survivors, all-causes deaths, and SCDs. HRT, mTWA, and DC values by subgroups shown in Table 3 . The majority of deaths (11 of 19 in the SCD subgroup and 6 of 10 in the all-causes subgroup) occurred within the first 3 months after enrollment that did not allow us to assess the trends of SCD predictors. In 6 patients who completed at least one study visit before death, a progressive insignificant decrease in LVEF from 40.7 ± 17.0% to 36.8 ± 15.7% (p = 0.097), and no significant HRT, mTWA, or DC changes were observed. According to Cox regression analysis, factors that significantly influenced the risk of overall mortality included LVEF, DC, HRT, HRV (SDNN, pNN50), mTWA at 05.00 AM and the daily number of PVCs (Table 4) .
Regarding SCD, the cut-off prognostic value of mTWA at 100 bpm was 52.5 µV (sensitivity 68.4%, specificity 60.0%) that was practically identical to the 12-months value (53.5 µV) (sensitivity 73.3%, specificity 64.6%), but the sensitivity and specificity Analysis of the combinations of several risk factors revealed that at 60 months of follow-up the risk of cardiovascular mortality was the highest in patients with LVEF <40% + VT during 24-hour ECG monitoring (OR 22.9 (95% CI: 2.6-200.4), p = 0.0001), while SCD risk was the highest in patients with LVEF <40%, impaired HRT and mTWA at 100 bpm > 53 µV (OR 24.8 (95 CI 2.6-237.2%) p = 0.002) compared with any of these parameters alone ( Fig. 1 and  2 ). Of note, the combination of LVEF <40% and VT during 24-hour ECG monitoring was only slightly inferior to the combination of LVEF <40%, impaired HRT and mTWA at 100 bpm > 53 µV. DC in combination with other non-invasive parameters moderately increased risk of both cardiovascular mortality and SCD.
Significance of various combinations of risk factors regarding overall mortality and SCD risk after adjustment for clinical covariates is shown in Fig. 1 and 2 . Survival curves are shown in Fig. 3 and ROC-curves for impaired HRT and mTWA combinations are shown in Fig. 4 .
Discussion
To our knowledge, this is the first investigation of long-term risk stratification for mortality using mTWA, HRT and DC in post-MI patients.
In prospective clinical studies of >10,000 patients, mTWA identified patients at risk for fatal arrhythmia and cardiovascular and total mortality [8] and met American Heart Association, American College of Cardiology, European Society of Cardiology, and/or Heart Rhythm Society requirements for class I (level of evidence A) and class IIa (level of evidence A) indications for arrhythmia risk assessment. [4] Goldberger et al. [1] stated that mTWA provides valuable information regarding the risk of cardiovascular mortality and SCD among patients with ischemic, dilated, and hypertrophic cardiomyopathies. Thus, a recent consensus guideline recommended mTWA monitoring in any suspected risk for fatal arrhythmia [8] but it has not been included in the ESC 2015 Guidelines for management of patients with ventricular arrhythmias and the prevention of SCD [11] due to the lack of evidence-based information.
Previously [12] we have demonstrated the significant predictive value of HRT and mTWA both in the general population of post-MI patients and in patients with preserved left ventricular function at 12 months of follow-up. No baseline characteristic typically linked with poor outcomes was associated with high mTWA, suggesting that mTWA offers complementary prognostic information. However, the subgroup analysis of patients with different LVEF at 60 months of follow-up virtually all investigated predictors showed no significant difference between subjects with preserved and reduced LV function, except low DC that remained significance in the subgroup of patients with LVEF > 40% (cardiovascular mortality: OR 8. Note: AUC, area under the ROC-curve; DC, deceleration capacity; LVEF, left ventricular ejection fraction; SDNN, standard deviation of normal to normal RR intervals; pNN50, proportion of the number of pairs of successive NNs that differ by more than 50 ms divided by total number of NNs; mTWA, microvolt T-wave alternans; HR, heart rate; ТО, turbulence onset; ТS, turbulence slope; PVC, premature ventricular contraction.
Figure 3a.
Cox regression for combination of HRT 2 and mTWA at HR 100 bpm > 53 mcV as a predictor of SCD at 12 months (А) [12] and 60 months (B). P values are for the log rank test.
Figure 3b
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Threshold values obtained in our study differed from findings in other studies [8, 14] that may be explained by differences in measurement and in characteristics of study populations, but cut-offs for mTWA at 05.00 AM (CV mortality) and mTWA at 100 bpm (SCD) at 12 and 60 months of follow-up were similar suggesting the good reproducibility of mTWA measurement during short-term and long-term monitoring; it is consistent with the results of Chan et al. [15] who showed that the predictive value of the baseline mTWA evaluation persists during 2-3 years, and therefore re-measurement mTWA is reasonable only every 2 years. In this study, duration of follow-up was 18 ± 11 months; our results for the follow-up period of 60 months confirm the conclusions of the authors [15] as repeated measurements at 3, 6 and 12 months were not significantly different.
Combined risk stratification at 60 months revealed that the risk of cardiovascular mortality was the highest in patients with LVEF <40% and the presence of VT, and the maximum risk of SCD was similar in patients with LVEF <40%, HRT 2 and mTWA at 100 bpm > 53 μV and patients with LVEF <40% and VT detection during ECG monitoring. This differs from the findings at 12 months, when the combination of HRT 2 and mTWA at 100 bpm > 53 μV defined the subgroup of the highest risk compared both with an isolated impairment of any indicator and other combinations, including those with LVEF < 40%. [12] This may be explained by the fact that most patients (15 of 19 in the SCD subgroup and 8 of 10 in the group of cardiovascular mortality) died within the first 12 months after enrollment. These patients were characterized by the maximum impairment of the studied parameters, and these dropouts resulted in the elimination of the highest-risk groups according to a combination of non-invasive predictors; in the remaining patients, "conventional" risk factors -the low LVEF and myocardial ectopic activity -became important. Again, this finding support the high short-term importance of these predictors.
In our study, the new predictors were more accurate than the conventional ones. While HRT has been used for over 10 years and is included in the International Guidelines for risk stratification in patients after myocardial infarction, data about the use of DC to predict adverse outcomes in high-risk groups are limited. [7, 16, 17, 18] However, DC has a number of advantages compared with conventional HRV: independent evaluation of parasympathetic (DC) and sympathetic system (acceleration capacity is used to assess the activity of the sympathetic system, but its prognostic value has not been demonstrated); simplicity of data presentation (only one component instead of multiple HRV parameters) and direct focus on the risk assessment, with a clear staging by the low, medium and high. [7] Several studies have shown prognostic significance of HRT 2 and DC ("severe autonomic failure") for the SCD risk stratification in the post-MI patients and preserved LVEF [16, 17] as well as in patients with CAD and diabetes. [18] In our study, this combination also was quite good for assessment of the risk of both overall mortality (4.3-fold), and SCD (4.4-fold) at 60 months.
Combined risk assessment with HRT and mTWA was first used by the REFINE study authors, [14] and subsequently by the other two study groups [19, 20] published later than our 12-months results. [12] Despite the fact that these studies had relatively long follow-ups (1.5 to 4 years) and the number of patients (173 to 322), included patients early after MI, differences in mTWA measurement and cut-off values, [19, 20] their findings of high prognostic significance of HRT 2 + mTWA confirm our data. Our study was the first one that used DC in a combined assessment of the risk of adverse outcomes and had the long follow-up up to 5 years. 
Figure 4b
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International Cardiovascular Forum Journal 11 (2017) DOI: 10.17987/icfj.v11i0.393 additional non-invasive examinations are performed (ventricular late potentials, HRV, unstable VT detection etc.), and in some cases -invasive electrophysiological study. There author considers ICD implantation justified only in case of positive result of the any additional tests. The more definitive answer may be received after the completion of a prospective REFINE-ICD study, which design includes randomization of patients with LVEF 36-50% and combined mTWA + HRT impairment for the standard treatment or ICD therapy. [5] In addition, long-term significance of noninvasive SCD predictors requires further confirmation in larger prospective studies.
Limitations
The single-center design, size of the study and number of events are limited; therefore, the findings require confirmation in a larger prospective study of high-risk subjects. This limitation was attenuated by adjustment for the well-known clinical and ECG risk factors. Despite the fact that post-MI population in our study was heterogenous and included patients with MI occurred from 2 months to about 30 years before enrollment, we analyzed possible effect of the MI onset on the noninvasive parameters; no significant influence was found; the heterogeneity of the previous MI treatment (invasive and non-invasive) was analyzed as well, and no significant impact was found. In addition, DC was evaluated retrospectively since this technique was unavailable at the study initiation.
Conclusions
Evaluation of HRT, DC and mTWA during 24-hour ECG monitoring may define the high risk of cardiovascular mortality and SCD in post-MI patients. The combination of abnormal HRT and mTWA100 > 53 μV is associated with the most significant increase in the risk of SCD during the first 12 months after the baseline examination. At 5 years of follow-up, value of noninvasive mortality predictors of the risk stratification is reduced compared with the importance of low LVEF and VT, but their contribution to a combined risk assessment remains significant. This suggest the high importance of these predictors for the short-term SCD and cardiovascular mortality risk stratification, indicating the need for more close monitoring and more aggressive therapy in these patients, as well as optimization of antiarrhythmic therapy to improve myocardial electrical stability or the selection of candidates for ICD implantation. 
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